Advancing thalamic neuromodulation in epilepsy: Bridging adult data to pediatric care

• Published in: Epilepsy research 2024-09, Vol.205, p.107407, Article 107407
• Main Authors: Samanta, Debopam, Aungaroon, Gewalin, Albert, Gregory W., Karakas, Cemal, Joshi, Charuta N., Singh, Rani K., Oluigbo, Chima, Perry, M. Scott, Naik, Sunil, Reeders, Puck C., Jain, Puneet, Abel, Taylor J., Pati, Sandipan, Shaikhouni, Ammar, Haneef, Zulfi
• Format: Article
• Language: English
• Subjects: Children; DBS; Deep brain stimulation; Electrical stimulation; Epilepsy; Neurostimulation; Responsive neurostimulation; RNS; Thalamic stimulation
• ISSN: 0920-1211; 1872-6844; 1872-6844
• DOI: 10.1016/j.eplepsyres.2024.107407

Thalamic neuromodulation has emerged as a treatment option for drug-resistant epilepsy (DRE) with widespread and/or undefined epileptogenic networks. While deep brain stimulation (DBS) and responsive neurostimulation (RNS) depth electrodes offer means for electrical stimulation of the thalamus in adult patients with DRE, the application of thalamic neuromodulation in pediatric epilepsy remains limited. To address this gap, the Neuromodulation Expert Collaborative was established within the Pediatric Epilepsy Research Consortium (PERC) Epilepsy Surgery Special Interest Group. In this expert review, existing evidence and recommendations for thalamic neuromodulation modalities using DBS and RNS are summarized, with a focus on the anterior (ANT), centromedian(CMN), and pulvinar nuclei of the thalamus. To-date, only DBS of the ANT is FDA approved for treatment of DRE in adult patients based on the results of the pivotal SANTE (Stimulation of the Anterior Nucleus of Thalamus for Epilepsy) study. Evidence for other thalamic neurmodulation indications and targets is less abundant. Despite the lack of evidence, positive responses to thalamic stimulation in adults with DRE have led to its off-label use in pediatric patients. Although caution is warranted due to differences between pediatric and adult epilepsy, the efficacy and safety of pediatric neuromodulation appear comparable to that in adults. Indeed, CMN stimulation is increasingly accepted for generalized and diffuse onset epilepsies, with recent completion of one randomized trial. There is also growing interest in using pulvinar stimulation for temporal plus and posterior quadrant epilepsies with one ongoing clinical trial in Europe. The future of thalamic neuromodulation holds promise for revolutionizing the treatment landscape of childhood epilepsy. Ongoing research, technological advancements, and collaborative efforts are poised to refine and improve thalamic neuromodulation strategies, ultimately enhancing the quality of life for children with DRE. •Thalamic neuromodulation represents an innovative treatment approach for drug-resistant epilepsy (DRE)•Anterior thalamic DBS is the sole FDA-approved treatment for adult DRE.•Despite limited evidence, pediatric epileptic care trends towards off-label thalamic neuromodulation use.•Neurologists and neurosurgeons from the Pediatric Epilepsy Research Consortium summarized literature on thalamic neuromodulation.•The review outlines future priorities to refine tha